Jane Street’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.58M | Sell |
12,906
-3,056
| -19% | -$605K | ﹤0.01% | 4623 |
|
|
2025
Q4 | $3.02M | Sell |
15,962
-35,897
| -69% | -$6.9M | ﹤0.01% | 4027 |
|
|
2025
Q3 | $9.19M | Buy |
51,859
+46,462
| +861% | +$6.91M | ﹤0.01% | 2527 |
|
|
2025
Q2 | $614K | Sell |
5,397
-31,525
| -85% | -$3.37M | ﹤0.01% | 6545 |
|
|
2025
Q1 | $3.88M | Buy |
36,922
+23,553
| +176% | +$2.66M | ﹤0.01% | 3309 |
|
|
2024
Q4 | $1.43M | Sell |
13,369
-1,083
| -7% | -$122K | ﹤0.01% | 4730 |
|
|
2024
Q3 | $1.45M | Sell |
14,452
-7,790
| -35% | -$784K | ﹤0.01% | 5124 |
|
|
2024
Q2 | $1.87M | Buy |
22,242
+3,245
| +17% | +$258K | ﹤0.01% | 4600 |
|
|
2024
Q1 | $1.39M | Buy |
18,997
+15,463
| +438% | +$1.14M | ﹤0.01% | 4795 |
|
|
2023
Q4 | $252K | Sell |
3,534
-12,883
| -78% | -$760K | ﹤0.01% | 7881 |
|
|
2023
Q3 | $984K | Buy |
16,417
+11,199
| +215% | +$737K | ﹤0.01% | 5205 |
|
|
2023
Q2 | $376K | Sell |
5,218
-1,509
| -22% | -$113K | ﹤0.01% | 6762 |
|
|
2023
Q1 | $495K | Buy |
+6,727
| New | +$478K | ﹤0.01% | 6338 |
|
|
2022
Q4 | – | Sell |
-21,905
| Closed | -$1.18M | – | 9686 |
|
|
2022
Q3 | $1.18M | Buy |
+21,905
| New | +$1.29M | ﹤0.01% | 5125 |
|
|
2022
Q1 | – | Sell |
-18,909
| Closed | -$1.37M | – | 10707 |
|
|
2021
Q4 | $1.82M | Buy |
18,909
+11,885
| +169% | +$1.1M | ﹤0.01% | 4661 |
|
|
2021
Q3 | $611K | Buy |
7,024
+2,630
| +60% | +$203K | ﹤0.01% | 6898 |
|
|
2021
Q2 | $360K | Sell |
4,394
-50,929
| -92% | -$4.24M | ﹤0.01% | 7845 |
|
|
2021
Q1 | $5.26M | Buy |
55,323
+40,514
| +274% | +$3.83M | ﹤0.01% | 2342 |
|
|
2020
Q4 | $919K | Sell |
14,809
-39,717
| -73% | -$2.26M | ﹤0.01% | 4798 |
|
|
2020
Q3 | $3.24M | Buy |
54,526
+26,342
| +93% | +$1.8M | ﹤0.01% | 2345 |
|
|
2020
Q2 | $1.97M | Buy |
+28,184
| New | +$1.79M | ﹤0.01% | 3092 |
|
|
2020
Q1 | – | Sell |
-37,440
| Closed | -$2.12M | – | 5694 |
|
|
2019
Q4 | $2.44M | Buy |
37,440
+29,933
| +399% | +$2M | ﹤0.01% | 1721 |
|
|
2019
Q3 | $466K | Sell |
7,507
-5,360
| -42% | -$337K | ﹤0.01% | 3625 |
|
|
2019
Q2 | $916K | Buy |
12,867
+8,279
| +180% | +$610K | ﹤0.01% | 2818 |
|
|
2019
Q1 | $360K | Sell |
4,588
-24,763
| -84% | -$1.88M | ﹤0.01% | 4054 |
|
|
2018
Q4 | $2.48M | Buy |
29,351
+18,114
| +161% | +$1.93M | 0.01% | 1504 |
|
|
2018
Q3 | $1.92M | Buy |
11,237
+8,388
| +294% | +$1.26M | ﹤0.01% | 1954 |
|
|
2018
Q2 | $368K | Buy |
2,849
+190
| +7% | +$21.2K | ﹤0.01% | 3923 |
|
|
2018
Q1 | $274K | Buy |
+2,659
| New | +$263K | ﹤0.01% | 4124 |
|
|
2017
Q3 | – | Sell |
-2,706
| Closed | -$205K | – | 4806 |
|
|
2017
Q2 | $205K | Sell |
2,706
-18,104
| -87% | -$1.27M | ﹤0.01% | 4014 |
|
|
2017
Q1 | $1.37M | Buy |
+20,810
| New | +$1.37M | 0.01% | 1718 |
|
|
2015
Q3 | – | Sell |
-21,897
| Closed | -$1.38M | – | 3910 |
|
|
2015
Q2 | $1.38M | Buy |
+21,897
| New | +$1.19M | 0.01% | 1283 |
|
|
2015
Q1 | – | Sell |
-8,175
| Closed | -$271K | – | 3337 |
|
|
2014
Q4 | $271K | Buy |
+8,175
| New | +$266K | ﹤0.01% | 1963 |
|
|
2014
Q3 | – | Sell |
-13,348
| Closed | -$519K | – | 2842 |
|
|
2014
Q2 | $519K | Buy |
+13,348
| New | +$542K | 0.01% | 1377 |
|
|
2013
Q3 | – | Sell |
-38,913
| Closed | -$908K | – | 2941 |
|
|
2013
Q2 | $908K | Buy |
+38,913
| New | +$700K | 0.02% | 981 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Jane Street's LGND Position: Q1 2026 in Review
Jane Street reduced its Ligand Pharmaceuticals (LGND) stake by 19% in Q1 2026, selling an estimated $605K and leaving 12,906 shares worth $2.58M. The position accounts for ﹤0.01% of the portfolio, ranked #4623.
Jane Street first reported a position in LGND in Q2 2013 and has held it in 35 quarters since. The position peaked at $9.19M in Q3 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Jane Street held 12,906 shares of Ligand Pharmaceuticals worth $2.58M as of Q1 2026.
- Jane Street sold 3,056 Ligand Pharmaceuticals shares in Q1 2026, an estimated $605K.
- Ligand Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #4623 holding.
- Jane Street first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 35 quarters since.
- Jane Street's Ligand Pharmaceuticals position peaked at $9.19M in Q3 2025.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.